-
91.发明公开公开(公告)号：US20230372303A1
公开(公告)日：2023-11-23
申请号：US18319380
申请日：2023-05-17
申请人： GLAUKOS CORPORATION
IPC分类号： A61K31/4178 , A61K47/18 , A61K9/00
CPC分类号： A61K31/4178 , A61K47/183 , A61K9/0014 , A61K9/0048
摘要： An ophthalmic topical cream composition includes a topical cream comprising at least one zwitterion; and an active pharmaceutical ingredient (API) dispersed in the topical cream. The ophthalmic topical cream composition and API are formulated for topical application and treatment of various disorders such as dry eye, presbyopia, intraocular pressure and blepharitis.
-
公开(公告)号：US20220233506A1
公开(公告)日：2022-07-28
申请号：US17587510
申请日：2022-01-28
申请人： Glaukos Corporation
IPC分类号： A61K31/4178 , A61K9/06 , A61K9/00 , A61K47/02 , A61K47/12 , A61K31/5575 , A61K31/46 , A61K31/498 , A61K31/56 , A61K31/27 , A61K38/13
摘要： Described herein are formulations including pharmaceutical agents comprising ester and/or lactone ring structures, and methods of using the same. The invention is also directed to a method and ophthalmic pharmaceutical compositions including solution and semisolid dosage forms (i.e. ophthalmic creams, gels, lotions, serums, and/or ointments) of treating a patient with various ocular diseases including presbyopia and dry eyes. The method comprising instructing a patient to apply one strip of the ophthalmic composition to the eyelids that includes pilocarpine or other active pharmaceutical ingredients containing ester and/or lactone ring structures with and without the buffering system.
-
公开(公告)号：US11376040B2
公开(公告)日：2022-07-05
申请号：US16132252
申请日：2018-09-14
申请人： GLAUKOS CORPORATION
发明人： Charles Raymond Kalina, Jr. , Todd N. Fjield , Douglas Daniel Crimaldi , Emma Claire Benjaminson , Tyler Joseph Brown , Richard William Martin
摘要： Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism/portion and/or a manual singulation mechanism/portion.
-
公开(公告)号：US20210186429A1
公开(公告)日：2021-06-24
申请号：US17128989
申请日：2020-12-21
申请人： GLAUKOS CORPORATION
摘要： Intraocular physiological sensor implants include a physiological sensor and a fluid pathway including a fluid inlet and a fluid outlet. The physiological sensor includes a sensing layer, a coil layer, and an integrated circuit layer. The intraocular pressure sensor provides trabecular bypass flow. The intraocular pressure sensor detects intraocular pressure, to identify patient conditions such as glaucoma.
-
公开(公告)号：US20210177656A1
公开(公告)日：2021-06-17
申请号：US17125466
申请日：2020-12-17
申请人： GLAUKOS CORPORATION
IPC分类号： A61F9/007
摘要： An instrument to perforate ocular tissue can include a handle configured to be grasped by a user, the handle including a proximal handle end and a distal handle end and a dissection cannula configured for at least partial insertion into a patient eye, wherein the dissection cannula can include a proximal cannula end configured to interface with the handle, a distal cannula or trephine end including an opening into a cannula bore, and an indicator spaced from the distal cannula end at a spacing to indicate or control insertion depth of the distal cannula end into the eye.
-
公开(公告)号：US10959941B2
公开(公告)日：2021-03-30
申请号：US15926930
申请日：2018-03-20
申请人： GLAUKOS CORPORATION
发明人： David S. Haffner
摘要： Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
-
-
-
公开(公告)号：US10245178B1
公开(公告)日：2019-04-02
申请号：US13490346
申请日：2012-06-06
申请人： Harold Heitzmann , Vanessa Tasso
发明人： Harold Heitzmann , Vanessa Tasso
摘要： Disclosed herein are drug delivery ocular implants comprising an elongate outer shell having a proximal end, and distal end and being shaped to define an interior lumen, at least one therepautic agent positioned within the lumen, wherein the outer shell has at least a first thickness, the outer shell comprises one or more regions of drug release, and the implant is dimensioned for implantation within the anterior chamber of the eye.
-
公开(公告)号：US09987472B2
公开(公告)日：2018-06-05
申请号：US12979249
申请日：2010-12-27
申请人： Hosheng Tu , Gregory T. Smedley , David Steven Haffner , Barbara A. Niksch , Richard A. Hill , Olav B. Bergheim
发明人： Hosheng Tu , Gregory T. Smedley , David Steven Haffner , Barbara A. Niksch , Richard A. Hill , Olav B. Bergheim
CPC分类号： A61M27/00 , A61F9/00781
摘要： Systems and methods for treating ocular disorders are disclosed. One system has a delivery instrument, with a non-linear axis, configured to be inserted into an anterior chamber of an eye and moved to a location proximate a physiologic outflow pathway of the eye. The delivery instrument carries an implant that has a distal end sized for insertion into tissue such that aqueous humor drains from the anterior chamber to the physiologic outflow pathway. One method involves inserting a non-linear portion of a delivery device into the anterior chamber to position an implant within the eye. Another method involves using a delivery device with a curved distal portion to implant an implant at a location communicating with the physiologic outflow pathway. The delivery can be through a corneal incision and the implant can comprise a drug.
-
-
-
-
-
-
-
-
-
搜索结果
161 条记录 (耗时 0.032 秒)
